Retatrutide appears to be a new medication in the fight against obesity. This revolutionary drug, classified as a dual GLP-1 and GIP receptor agonist, shows promising results in research studies. By stimulating these receptors, Retatrutide controls cravings, {promotesenergy expenditure, and ultimately contributes to significant reduction in body ma